

Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating β -catenin

Jianwei Zhang

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Zhongmin Lan

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Guotong Qiu

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

Hu Ren

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Yajie Zhao

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Zongting Gu

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Zongze Li

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Lin Feng

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Jin He

Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine

Chengfeng Wang (✉ wangchengfeng62@163.com)

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital of Skin Diseases and Institute of Dermatology

Research article

Keywords: pancreatic cancer, ANP32E, proliferation, migration, β -catenin

Posted Date: August 27th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-27702/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on November 4th, 2020. See the published version at <https://doi.org/10.1186/s12885-020-07556-z>.

Abstract

Background: Pancreatic cancer is a malignant tumor with high mortality. Acidic nuclear phosphoprotein 32 family member E (ANP32E), a specific H2A.Z chaperone, has been shown to contribute to breast cancer development. However, the significance of ANP32E in pancreatic cancer is poorly understood. This study aimed to investigate the role of ANP32E in pancreatic cancer.

Methods: The expression of ANP32E in 179 pancreatic cancer tissues and 171 normal tissues, and the correlation between ANP32E expression and patients' survival were analyzed from the TCGA database. ANP32E was over-expressed and silenced using lentivirus. siRNA was used to knock down β -catenin. CCK8, colony formation, cell cycle and transwell experiments were performed to determine cell proliferation and migration. qRT-PCR and Western blot were conducted to detect mRNA and protein expression.

Results: ANP32E was up-regulated in pancreatic cancer tissues and cells. Up-regulation of ANP32E predicted poor prognosis in pancreatic cancer patients. Lentivirus-mediated knockdown of ANP32E suppressed the proliferation, colony growth and migration of PANC1 and MIA cells. By contrast, ANP32E over-expression promoted the proliferation and migration of both cells. In addition, ANP32E accelerated the cell cycle progression in PANC1 and MIA cells. Molecular experiments showed that ANP32E activated β -catenin/cyclin D1 signaling. Silencing of β -catenin reduced cell proliferation and migration in ANP32E over-expressed cells.

Conclusion: Our results propose that ANP32E functions as an oncogene in pancreatic cancer via activating β -catenin.

Background

Pancreatic ductal adenocarcinoma (PDAC) is the commonest malignancy of the pancreas, with approximately 367,000 newly diagnosed cases and 359,000 PDAC-related deaths worldwide in 2015 [1]. The major risk factors for pancreatic cancer include tobacco smoking, alcohol use, type II diabetes, chronic pancreatitis [2]. Various genetic studies and fundamental experiments have shown that genetic variants of KRAS, CDKN2A, TP53 and SMAD4 contribute to the disease progression of pancreatic cancer. However, based on current information from the pharmacy companies or clinical studies, none of these genes are easily targeted. Thus, identifying new driver genes may help develop effective drugs against this deadly disease.

H2A.Z is a pivotal histone variant involved in regulating transcriptional activation or inhibition. It is essential for the survival and development in *Drosophila* and mouse [3, 4]. As a specific H2A.Z histone chaperon, acidic nuclear phosphoprotein 32 family member E (ANP32E) removes the H2A.Z from transcriptional region of the target genes to regulate their expression [5, 6]. ANP32E plays an important role in cerebellar development and synaptogenesis [7, 8]. Dys-regulation of ANP32E contributes to the migration and invasion of breast cancer cells [9]. Overexpression of ANP32E promotes the triple-negative

breast carcinogenesis through up-regulating E2F1 [10]. However, the involvement of ANP32E in pancreatic cancer is unclear.

Here in this study, we explored the expression and function of ANP32E in pancreatic cancer. ANP32E was up-regulated in pancreatic cancer tissues. Up-regulation of ANP32E promoted the proliferation, colony growth and migration of pancreatic cancer cells. The apoptosis was suppressed by ANP32E. Mechanistically, ANP32E induced the expression of β -catenin and its down-stream target cyclin D1. Overexpression of β -catenin rescued the viability inhibited by ANP32E knockdown. Our study highlights the oncogenic role ANP32E in pancreatic cancer.

Methods

TCGA analysis of ANP32E expression in pancreatic patients

The transcript level of ANP32E in pancreatic cancer tissues and normal tissues and the survival information of the patients were downloaded from The Cancer Genome Atlas (<http://cancergenome.nih.gov>) database. A total of 179 tumor tissues and 175 normal tissues were included to analyze the expression of ANP32E. A total of 89 patients with ANP32E high expression and 89 patients with low expression was included to determine the correlation between ANP32E expression and patients' survival.

Cell culture

Human normal ductal epithelial cells of the pancreas HPDE and pancreatic cancer cells AsPC1, PANC1 and MIA were obtained from ATCC. The cells were cultured in Dulbecco modified Eagle's medium (DMEM, Hyclone), which contained 10% fetal bovine serum (FBS, Gibco) and 1% penicillin and streptomycin (Corning). The cell culture was maintained in a 37°C incubator with 5% CO₂.

ANP32E knockdown

Lentivirus vector system pGCSIL-GFP (with a GFP marker), Helper2.0 (VSVG element) and pHelper1.0 (gag/pol element) was used to knock down ANP32E in PANC1 and MIA cells. Targeting sequence of the Ctrl, ANP32E#1 and ANP32E#2 was 5'-TTCTCCGAACGTGTCACGT-3', 5'-GTCCACCGGAAGGATATGA-3' and 5'-GCCTCTCATACTTAATGAA-3'. The lentivirus was packaged by co-transfecting the pGCSIL-GFP, Helper2.0 and pHelper1.0 to 293FT cells. The knockdown efficiency was detected by qRT-PCR and Western blot.

ANP32E overexpression

Lentivirus vector system pCDH, PSPAX2 and PDM2G was used to over-express ANP32E in PANC1 and MIA cells. Coding sequence of ANP32E was cloned into the pCDH vector, which contained a GFP marker. Lentivirus was packaged by co-transfecting the pCDH, PSPAX2 and PDM2G to 293FT cells. Overexpression abundance was detected by qRT-PCR and Western blot.

β-catenin interference

The siRNAs against CTNNB or negative control were synthesized from GenePharma company. The transfection of the siRNAs were conducted using RNAimax (Invitrogen), following the following to the manufacturer's instructions. The targeted sequence of siRNA was as followed: siCTNNB, 5'-CCCACTAATGTCCAGCGTT-3'; and siCtrl, 5'-TTCTCCGAACGTGTCACGT-3'.

RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)

PANC1 and MIA cells were lysed using Trizol reagent. Total RNA was extracted from the cells and subjected to reverse transcription reaction with M-MLV reverse transcriptase (Promega). Quantification of the cDNA was performed with SYBR master mixture on the Biorad machine. The qPCR primer sequence was as followed: ANP32E forward, 5'-TGCCTGTGTGTCAATGGGG-3', and reverse, 5'-GCAGAGCTTCTACTGTACTGAGA-3'; and GAPDH forward, 5'-TGACTTCAACAGCGACACCCA-3', and reverse, 5'-CACCTGTTGCTGTAGCCAAA-3. The expression ANP32E was normalized to GAPDH.

Western blot

Total protein was extracted from PANC1 and MIA cells with RIPA lysis buffer (Beyotime). BCA experiment (Beyotime) was conducted to measure the protein concentration. Equal amount of the protein was separated on 10-12% SDS-PAGE gels. Subsequently, the proteins were transferred onto PVDF membranes. 5% skim milk was used to block the membranes for 1 hour at room temperature. The membranes were incubated with indicated primary antibodies at 4°C overnight. Antibody against ANP32E was from Abcam. β-actin primary antibody and the secondary antibodies were obtained from SantaCruz.

CCK8 assay

Cell proliferation was determined by CCK8 assay. Briefly, ANP32E silenced or over-expressed and its control cells were seeded into 96-well plates at the density of 2000 cells per well. The cells were cultured for 4 days. 1, 2, 3 and 4 days later, 10% the CCK8 reagent (YEASEN) was added into each well and the plates were maintained at 37°C. 3 hours later, the OD value at 450 nm was measured on the micro-plate machine. The cell viability was normalized to the OD value of the first day.

Colony formation assay

A total of 500 shCtrl, shANP32E#1 and shANP32E#2, OE-Ctrl and OE-ANP32E PANC1 and MIA cells were seeded into the 6-well plates. 10 days later, colonies were formed and the cell culture was removed. After washed by PBS for three times, the colonies were fixed by methanol and stained by crystal violet. Subsequently, the plates were washed by clean water and dried at room temperature. Then the colonies were photographed by the camera.

Cell cycle analysis

PI staining was used to analyze the cell cycle in PANC1 and MIA cells. Indicated cells were seeded in triplicate in 6-well plates. 2 days later, the cells were re-suspended in FBS free culture medium and fixed by 70% ethanol. After stained by PI reagent, flow cytometer was used to analyze the cell cycle distribution in PANC1 and MIA cells.

Transwell assay

A total of 3×10^4 PANC1 or MIA cells in 200ul FBS free culture medium were seeded onto the upper surface of 8.0- μ m filter migration chambers. The lower compartment contained 500ul DMEM medium with 10% FBS. 24 hours later, the cells attached on the upper surface were removed using cotton tips. The cells on the lower surface were fixed by methanol and stained by crystal violet. The images were photographed under a microscope.

Statistical analysis

Graphpad prism software was used to analyze the data as shown in the Figure. Students't tests were used to determine the difference between two groups. One-way ANOVA was used to determine the difference when more than two groups. Statistical difference was considered significant when $p < 0.05$.

Results

ANP32E is over-expressed in pancreatic cancers and predicts the survival of patients

To study the clinical relevance of ANP32E in pancreatic cancer, we downloaded the transcript abundance of ANP32E and the patients' survival information from TCGA database. We found that ANP32E was over-expressed in pancreatic cancer tissues comparing to normal pancreatic tissues (Fig. 1A). The pancreatic cancer patients were divided into two groups: ANP32E low expression and high expression group. Survival curve showed that ANP32E high expression patients exhibited poorer overall and disease free survival than those with ANP32E low expression (Fig. 1B and 1C). We also checked the abundance of ANP32E in human normal ductal epithelial cells of the pancreas HPDE and pancreatic cancer cells AsPC1, PANC1 and MIA. qRT-PCR and Western blot results showed HPDE had lowest ANP32E expression comparing with AsPC1, PANC1 and MIA (Fig. 1D). These results suggest that ANP32E is correlated with the disease progression of pancreatic cancer.

ANP32E promotes the proliferation and growth of pancreatic cancer cells

To determine whether ANP32E functions as an oncogene in pancreatic cancer, we used lentivirus to knock down ANP32E in pancreatic cancer cells PANC1 and MIA. qRT-PCR and Western blot results showed that ANP32E was efficiently knocked down in PANC1 and MIA cells (Fig. 2A and 2B). We also used lentivirus vector system to over-express ANP32E. Comparing with Ctrl cells, ANP32E over-expressed cells had significantly higher mRNA and protein abundance of ANP32E (Fig. 2C and 3D). These results suggest that ANP32E is efficiently silenced and over-expressed in PANC1 and MIA cells.

To examine the effect of ANP32E on cell proliferation, CCK8 assays were performed in ANP32E knockdown and over-expressed cells. We found that down-regulation of ANP32E suppressed the proliferation of PANC1 and MIA cells (Fig. 3A). By contrast, up-regulation of ANP32E enhanced the cell viability of both cells (Fig. 3B). Consistently, ANP32E silencing and overexpression reduced and enhanced the colony formation capacity in PANC1 and MIA cells, respectively (Fig. 3C-3F). Collectively, ANP32E functions as an oncogene in pancreatic cancer.

ANP32E promotes the migration of pancreatic cancer cells

Next, we assessed the role of ANP32E on pancreatic cancer cell migration. Transwell assay was conducted to evaluate the migration capacity in ANP32E knockdown and over-expressed PANC1 and MIA cells. The results showed that ANP32E overexpression promoted the migration in PANC1 and MIA cells (Fig. 4A and 4B). Moreover, comparing to shCtrl PANC1 and MIA cells, shANP32E#1 and shANP32E#2 cells exhibited reduced migration capacity (Fig. 4C). Collectively, ANP32E enhanced the migration of pancreatic cancer cells.

ANP32E promotes the cell cycle progression in pancreatic cancer cells

Accelerated cell cycle process is a hallmark of cancer cell. We examined the effect of ANP32E on cell cycle distribution. PANC1 and MIA cells infected with ANP32E overexpression lentivirus were stained with PI and subjected to flow cytometer analysis of cell cycle. Ectopic expression of ANP32E led to reduced G0 phase and increased S and G2/M phase (Fig. 5A and 5B). These results indicate that ANP32E promotes cell cycle progression.

ANP32E up-regulates β -catenin to promote the proliferation and migration of pancreatic cancer cells

We attempted to explore the down-stream targets of ANP32E using Western blot assays. We found the expression of β -catenin and cyclin D1 was increased in ANP32E over-expressed MIA cells (Fig. 6A). Oppositely, ANP32E down-regulation inhibited the expression of β -catenin and cyclin D1 (Fig. 6A). Consistent results were observed in ANP32E over-expressed and silenced PANC1 cells (Fig. 6B). To evaluate whether β -catenin contributes to the oncogenic role of ANP32E in pancreatic cancer, we knocked down CTNNB, which encodes β -catenin, in ANP32E over-expressed PANC1 and MIA cells. Western blot showed that β -catenin was efficiently silenced in PANC1 cells (Fig. 6C). Down-regulation of β -catenin significantly repressed the proliferation and migration of PANC1 and MIA cells (Fig. 6D and 6E). These results suggest that ANP32E promotes pancreatic cancer through potentiating β -catenin signaling.

Discussion

Pancreatic cancer is a lethal malignancy. Once diagnosed, the disease progresses fast and the 5-year survival rate is very low. To identify novel oncogenes or tumor suppressors may help develop effective drugs to cure this malignancy. In this study, we found that ANP32E was an oncogene in pancreatic cancer. High expression of ANP32E was found in PAAD tissues and predicted poor survival of PAAD

patients. *In vitro*, ANP32E promoted the proliferation, colony formation and migration of pancreatic cancer cells. ANP32E also regulated cell cycle and apoptosis in these cells. β -catenin/cyclin D1 signaling was positively regulated by ANP32E. Inhibition of β -catenin reduced the proliferation of pancreatic cancer cells. These findings indicate that ANP32E promotes pancreatic cancer through regulating β -catenin/cyclin D1 signaling.

Acidic nuclear phosphoprotein 32 family member E (ANP32E) is a specific H2A.Z histone chaperon. It regulates the expression of target genes by promoting the removal of H2A.Z from transcriptional region of the genes [5, 6]. Anp32e also plays a pivotal role in nucleosome reorganization and DNA repair by removing H2A.Z from DNA double-strand breaks [11]. Several studies have investigated the role of ANP32E in cancer development. For example, Li et.al showed that miR-141 repressed the proliferation and migration of breast cancer cells and the expression of ANP32E. Knockdown of ANP32E reduced cell viability [9]. Thus, ANP32E contributes to the tumor suppressive role of miR-141 in breast cancer. In addition, ANP32E promotes the development of triple-negative breast cancer via transcriptionally activating E2F1 [10]. These results indicate that ANP32E maybe an oncogene in cancers. In this study, we observed that ANP32E was up-regulated in PAAD tissues. ANP32E expression was also inversely correlated with the prognosis of PAAD patients. *In vitro*, ANP32E overexpression promoted the proliferation, colony formation and migration of PANC1 and MIA cells. Opposite results were found in ANP32E silenced cells. Furthermore, ANP32E suppressed apoptosis and promoted cell cycle progression in PANC1 and MIA cells. Our results demonstrate that ANP32E functions as an oncogene in pancreatic cancer.

Due to alterations of any component of Wnt/ β -catenin signaling pathway, it is frequently activated in various cancers, including colorectal cancer, hepatocellular carcinoma and pancreatic cancer [12-14]. In brief, Wnt ligand binds to Frizzled receptor family, leading to inactivation of adenomatous polyposis coli (APC) or axin, which in turn promotes the cytoplasmic accumulation and nuclear localization of β -catenin. β -catenin can also be regulated by other factors to promote cancer development. For instance, TYRO3 promotes the proliferation and metastasis of gastric cancer cells through activation of Wnt/ β -catenin signaling pathway [15]. LncCCAT1 enhances the functions of breast cancer stem cell via activating WNT/ β -catenin signaling [16]. β -catenin is a transcriptional factor that interacts with TCF/LEF factors to activate the expression of target genes. The well-known downstream targets for β -catenin are c-myc and cyclin D1 [17, 18]. However, the correlation between ANP32E and β -catenin is unclear in pancreatic cancer. Here, our molecular experiments showed that ANP32E up-regulated β -catenin and its downstream target cyclin D1. We also checked other oncogenes, such as PKM2 and HK2, or tumor suppressors, including P53 and PTEN. No difference was observed after knocking down ANP32E. We also analyzed the role of β -catenin in ANP32E over-expressed cells. The results showed that knockdown of β -catenin reduced the viability of pancreatic cancer cells with highly expressed ANP32E. These results reveal that ANP32E promotes pancreatic cancer through activating β -catenin.

Conclusions

We demonstrate that ANP32E is an oncogene in pancreatic cancer. ANP32E promotes the proliferation and migration through up-regulation and activation of β -catenin/cyclin D1 signaling. Up-regulation of ANP32E in PAAD tissues and the inverse relationship between ANP32E expression and patients' survival indicate that ANP32E maybe a diagnosed biomarker for PAAD. Our findings suggest that ANP32E is a promising therapeutic target for PAAD.

Abbreviations

ANP32E, Acidic nuclear phosphoprotein 32 family member E; PDAC, pancreatic ductal adenocarcinoma; TCGA, The Cancer Genome Atlas; DMEM, Dulbecco modified Eagle's medium; FBS, fetal bovine serum; qRT-PCR, quantitative real-time polymerase chain reaction; APC, adenomatous polyposis coli.

Declarations

Ethics approval and consent to participate

Ethics approval is not required for the use of the cells in our study.

Consent for publication

No consent is required in this study.

Availability of data and material

All data generated or analyzed during this study are included in this published article.

Competing interests

These authors declare no conflicts of interest.

Funding

The research was financially supported by National High Technology Research and Development Program of China (2012AA022701) and CAMS Initiation Fund for Mediacal Sciences (2016-I2M-1-001). The funders mentioned were used for purchasing the experiments materials but not for study design and data analysis.

Authors' contributions

JWZ, JH and CFW designed the study. JWZ, ZML, GTQ and HR performed the experiments. JWZ, YJZ, ZTG, ZZL, LF and CFW analyzed the data. JWZ, JH and CFW wrote the manuscript draft and revised the draft. All authors have read and approved the manuscript

Acknowledgements

Not Applicable.

References

1. RL S, KD M, A J: **Cancer statistics, 2015**. *CA Cancer J Clin* 2015, **65**(1):5-29.
2. J K, M K, M A, C LV, CD J, AV B, RE N, M T, DA T, RH H *et al*: **Pancreatic cancer**. *Nature reviews Disease primers* 2016, **2**:16022.
3. MJ C, JR W, F G, R S, DJ T: **Regions of variant histone His2AvD required for Drosophila development**. *Nature* 1999, **399**(6737):694-697.
4. Faast R, Thonglairoam V, Schulz TC, Beall J, Wells JR, Taylor H, Matthaei K, Rathjen PD, Tremethick DJ, Lyons I: **Histone variant H2A.Z is required for early mammalian development**. *Curr Biol* 2001, **11**(15):1183-1187.
5. Farris SD, Rubio ED, Moon JJ, Gombert WM, Nelson BH, Krumm A: **Transcription-induced chromatin remodeling at the c-myc gene involves the local exchange of histone H2A.Z**. *J Biol Chem* 2005, **280**(26):25298-25303.
6. Mao Z, Pan L, Wang W, Sun J, Shan S, Dong Q, Liang X, Dai L, Ding X, Chen S *et al*: **Anp32e, a higher eukaryotic histone chaperone directs preferential recognition for H2A.Z**. *Cell Res* 2014, **24**(4):389-399.
7. Jiang M, Ma Y, Ni X, Cao G, Ji C, Cheng H, Tang R, Xie Y, Mao Y: **Molecular cloning and characterization of a novel human gene (ANP32E alias LANPL) from human fetal brain**. *Cytogenet Genome Res* 2002, **97**(1-2):68-71.
8. Radrizzani M, Vila-Ortiz G, Cafferata EG, Di Tella MC, Gonzalez-Guerrico A, Perandones C, Pivetta OH, Carminatti H, Idoyaga Vargas VP, Santa-Coloma TA: **Differential expression of CPD1 during postnatal development in the mouse cerebellum**. *Brain Res* 2001, **907**(1-2):162-174.
9. Li P, Xu T, Zhou X, Liao L, Pang G, Luo W, Han L, Zhang J, Luo X, Xie X *et al*: **Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: involvement of ANP32E targeting**. *Cancer Med* 2017, **6**(3):662-672.
10. Xiong Z, Ye L, Zhenyu H, Li F, Xiong Y, Lin C, Wu X, Deng G, Shi W, Song L *et al*: **ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1**. *Mol Oncol* 2018, **12**(6):896-912.
11. Gursoy-Yuzugullu O, Ayrapetov MK, Price BD: **Histone chaperone Anp32e removes H2A.Z from DNA double-strand breaks and promotes nucleosome reorganization and DNA repair**. *Proc Natl Acad Sci U S A* 2015, **112**(24):7507-7512.
12. Fodde R, Smits R, Clevers H: **APC, Signal transduction and genetic instability in colorectal cancer**. *Nature Reviews Cancer* 2001, **1**(1):55-67.
13. Klaus A, Birchmeier W: **Wnt signalling and its impact on development and cancer**. *Nature Reviews Cancer* 2008, **8**(5):387-398.

14. Morris JP, Wang SC, Hebrok M: **KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.** *Nature Reviews Cancer* 2010, **10**(10):683-695.
15. D C, Q L, G C, W Z: **TYRO3 facilitates cell growth and metastasis via activation of the Wnt/ β -catenin signaling pathway in human gastric cancer cells.** *Aging* 2020, **12**.
16. T T, C G, T X, R Z, K Z, Y P, L J: **LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/ β -catenin Signaling.** *Theranostics* 2019, **9**(24):7384-7402.
17. N Z, X C: **A positive feedback loop involving the LINC00346/ β -catenin/MYC axis promotes hepatocellular carcinoma development.** *Cell Oncol (Dordr)* 2020, **43**(1):137-153.
18. S G, A G, S X, Z Y, S N, Y Z, D P: **PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3 β / β -catenin/cyclin D1 signaling pathway in ER-negative breast cancer.** *Journal of experimental & clinical cancer research : CR* 2017, **36**(1):179.

Figures




Figure 1

Clinical relevance of ANP32E in pancreatic cancer patients. (A) The transcript abundance of ANP32E in pancreatic adenocarcinoma tissues ($n=179$) and normal tissues ($n=175$). $p<0.001$. (B) Pancreatic adenocarcinoma patients were divided into ANP32E high expression ($n=45$) and low expression ($n=45$) group and subjected to disease free survival analysis. $p=0.045$. (C) Pancreatic adenocarcinoma patients were divided into ANP32E high expression ($n=89$) and low expression ($n=89$) group and subjected to

overall survival analysis. $p=0.049$. (D) qRT-PCR and Western blot analysis of ANP32E in human normal ductal epithelial cells of the pancreas HPDE and pancreatic cancer cells AsPC1, PANC1 and MIA. $*p<0.05$. $**p<0.01$.




Figure 2

ANP32E is efficiently knocked down and over-expressed in MIA and PANC1 cells. (A and B) qRT-PCR (A) and Western blot (B) analysis of ANP32E in shCtrl, shANP32E#1 and shANP32E#2 MIA and PANC1 cells. $**p<0.01$. (C and D) qRT-PCR (C) and Western blot (D) results of ANP32E in Ctrl and ANP32E over-expressed MIA and PANC1 cells. $**p<0.01$.




Figure 3

ANP32E promotes the proliferation and colony growth of pancreatic cancer cells. (A) shCtrl, shANP32E#1 and shANP32E#2 MIA and PANC1 cells were subjected to CCK8 analysis of cell proliferation. * $p < 0.05$. ** $p < 0.01$. (B) Ctrl and ANP32E over-expressed PANC1 and MIA cells were subjected to CCK8 analysis of cell proliferation. * $p < 0.05$. ** $p < 0.01$. (C and D) shCtrl, shANP32E#1 and shANP32E#2 MIA (C) and PANC1(D) cells were subjected to colony formation assays. Left, colony images. Right, quantification result. * $p < 0.05$. ** $p < 0.01$. (E and F) Ctrl and ANP32E over-expressed MIA (E) and PANC1 (F) cells were subjected to colony formation assays. Left, colony images. Right, quantification result. * $p < 0.05$.




Figure 4

ANP32E promotes migration of the pancreatic cancer cells. (A) Transwell assay was performed to analyze the migration in Ctrl and ANP32E over-expressed MIA cells. Left, cell images. Right, quantification result. $**p < 0.01$. (B) Transwell assay was performed to analyze the migration in Ctrl and ANP32E over-expressed PANC1 cells. Left, cell images. Right, quantification result. $**p < 0.01$. (C) Transwell assay was performed to analyze the migration in shCtrl, shANP32E#1 and shANP32E#2 MIA and PANC1 cells. Left, cell images. Right, quantification result. $**p < 0.01$.




Figure 5

ANP32E regulates cell cycle in pancreatic cancer cells. (A) Cell cycle distribution of Ctrl and ANP32E over-expressed MIA cells. Left, cell cycle images. Right, quantification result. * $p < 0.05$. (B) Cell cycle distribution of Ctrl and ANP32E over-expressed PANC1 cells. Left, cell cycle images. Right, quantification result. * $p < 0.05$.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryfileWesternblot.pdf](#)